{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:05:43Z","timestamp":1780553143543,"version":"3.54.1"},"reference-count":149,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gastrointestinal (GI) cancers, encompassing esophageal, gastric, colorectal, hepatocellular, and pancreatic cancers, represent a major global health burden with persistently high morbidity and mortality. Given the limited therapeutic options and poor prognoses for patients with advanced-stage disease, there is an urgent and unmet clinical need for novel targeted therapies. Cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors (such as palbociclib, ribociclib, and abemaciclib) exert their effects by arresting the cell cycle at the G1\/S checkpoint. Their landmark clinical success in hormone receptor-positive breast cancer has highlighted the therapeutic potential of targeting cell cycle regulation, thereby prompting extensive investigation into their application in solid tumors of the digestive system. Emerging evidence indicates that, beyond their direct antiproliferative effects, CDK4\/6 inhibitors profoundly remodel the tumor immune microenvironment (TIME). By enhancing tumor antigen presentation, diminishing the immunosuppressive activity of regulatory T cells (Tregs), and promoting effector T cell infiltration, these agents provide a robust mechanistic rationale for synergistic combinations with immune checkpoint inhibitors (ICIs). However, the frequent dysregulation of the CDK4\/6-RB pathway and the inherently complex TIME in digestive cancers often precipitate primary and acquired drug resistance, which restricts their clinical efficacy. Consequently, elucidating the mechanisms that modulate drug sensitivity and developing biomarker-driven combination regimens have become critical research priorities. This review systematically summarizes the mechanisms governing the sensitivity of digestive tract tumors to CDK4\/6 inhibitors. From the perspective of laboratory medicine, we further emphasize the importance of biomarker detection, therapeutic target assessment, and precision molecular subtyping in identifying patients most likely to benefit from CDK4\/6 inhibitor-based therapies. In addition, we discuss the role of these agents in remodeling the TIME, evaluate current combination strategies aimed at overcoming resistance, and highlight future directions for advancing this rapidly evolving field.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1845921","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:35:50Z","timestamp":1780551350000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CDK4\/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers"],"prefix":"10.3389","volume":"17","author":[{"given":"Junhao","family":"Cui","sequence":"first","affiliation":[{"name":"Sichuan Key Laboratory of Medical Molecular Testing, College of Medical Technology, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sichuan Key Laboratory of Medical Molecular Testing, College of Medical Technology, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfang","family":"Wu","sequence":"additional","affiliation":[{"name":"Sichuan Key Laboratory of Medical Molecular Testing, College of Medical Technology, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Fifth People\u2019s Hospital Affiliated to Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lan","sequence":"additional","affiliation":[{"name":"Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, Institute of Breast Health Medicine, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingshuang","family":"Wang","sequence":"additional","affiliation":[{"name":"Sichuan Key Laboratory of Medical Molecular Testing, College of Medical Technology, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting cdk4 and cdk6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s43018-024-00893-z","article-title":"Resistance mechanisms and therapeutic strategies of cdk4 and cdk6 kina se targeting in cancer","volume":"6","author":"Asciolla","year":"2025","journal-title":"Nat Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Sci (New York NY)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","article-title":"The cdk4\/6 inhibitor revolution - a game-changing era for breast cance r treatment","volume":"21","author":"Morrison","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of hr+, her2-, node-positive, high-risk, early breast cancer (monarch e)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02086","article-title":"Abemaciclib plus fulvestrant in advanced breast cancer after progressi on on cdk4\/6 inhibition: Results from the phase iii postmonarch trial","volume":"43","author":"Kalinsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47060454","article-title":"Development of cdk4\/6 inhibitors in gastrointestinal cancers: Biomarke rs to move forward","volume":"47","author":"Voutsadakis","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02097-4","article-title":"Digestive cancers: Mechanisms, therapeutics and management","volume":"10","author":"Zhan","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mor tality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104148","article-title":"The cdk4\/6 inhibitors biomarker landscape: The most relevant biomarker s of response or resistance for further research and potential clinica l utility","volume":"192","author":"Antonarelli","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188912","article-title":"Immunomodulatory effects of cdk4\/6 inhibitors","volume":"1878","author":"Zhang","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1158\/1541-7786.MCR-23-0045","article-title":"Significance of rb loss in unlocking phenotypic plasticity in advanced cancers","volume":"21","author":"Venkadakrishnan","year":"2023","journal-title":"Mol Cancer Res MCR"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, cdks and cancer: A changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2025.04.001","article-title":"The rb protein: More than a sentry of cell cycle entry","volume":"31","author":"Thangavelu","year":"2025","journal-title":"Trends Mol Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321000","article-title":"Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer","volume":"70","author":"Knudsen","year":"2021","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-025-01080-7","article-title":"Efficacy of cdk4\/6 inhibition in colorectal cancer and the role of p16 expression in predicting drug resistance","volume":"48","author":"Schneider","year":"2025","journal-title":"Cell Oncol (Dordrecht Netherlands)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2021.01.010","article-title":"New insights into cdk regulators: Novel opportunities for cancer thera py","volume":"31","author":"Bury","year":"2021","journal-title":"Trends Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-023-10158-3","article-title":"Colorectal cancer: A comprehensive review of carcinogenesis, diagnosis , and novel strategies for classified treatments","volume":"43","author":"Abedizadeh","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet (London England)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7150\/thno.56539","article-title":"Mutational spectrum and precision oncology for biliary tract carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114320","article-title":"P16 methylation is a potential predictive marker for abemaciclib sensi tivity in gastric cancer","volume":"183","author":"Bae","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"B26","article-title":"Abnormal p16 expression and prognostic significance in esophageal squa mous cell carcinoma","volume":"39","author":"Jiang","year":"2024","journal-title":"Histol Histopathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223084","article-title":"P16 methylation increases the sensitivity of cancer cells to the cdk4\/ 6 inhibitor palbociclib","volume":"14","author":"Li","year":"2019","journal-title":"PLoS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3663","article-title":"P27 as a transcriptional regulator: New roles in development and cance r","volume":"80","author":"Razavipour","year":"2020","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2174\/1381612829666230306123455","article-title":"The interplay between noncoding rnas and p21 signaling in gastrointest inal cancer: From tumorigenesis to metastasis","volume":"29","author":"Rahmani","year":"2023","journal-title":"Curr Pharm Des"},{"key":"B30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41419-021-04241-2","article-title":"P27kip1 expression and phosphorylation dictate palbociclib sensitivity in kras-mutated colorectal cancer","volume":"12","author":"Rampioni Vinciguerra","year":"2021","journal-title":"Cell Death Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3892\/ol.2020.12397","article-title":"Function of p21 and its therapeutic effects in esophageal cancer","volume":"21","author":"Wang","year":"2021","journal-title":"Oncol Lett"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112886","article-title":"Frmd8 targets both cdk4 activation and rb degradation to suppress colo n cancer growth","volume":"42","author":"Yu","year":"2023","journal-title":"Cell Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00783-5","article-title":"Mutational analysis of microsatellite-stable gastrointestinal cancer w ith high tumour mutational burden: A retrospective cohort study","volume":"24","author":"Wang","year":"2023","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30704","article-title":"Dependency of cholangiocarcinoma on cyclin d-dependent kinase activity","volume":"70","author":"Sittithumcharee","year":"2019","journal-title":"Hepatol (Baltimore Md)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12967-017-1231-7","article-title":"Cdk4\/6 inhibitor-shr6390 exerts potent antitumor activity in esophagea l squamous cell carcinoma by inhibiting phosphorylated rb and inducing g1 cell cycle arrest","volume":"15","author":"Wang","year":"2017","journal-title":"J Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.733478","article-title":"Identification of potential biomarkers for liver cancer through gene m utation and clinical characteristics","volume":"11","author":"Cui","year":"2021","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-023-01458-9","article-title":"E3 ligase mg53 suppresses tumor growth by degrading cyclin d1","volume":"8","author":"Fang","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1026512","article-title":"Fbxo4 loss facilitates carcinogen induced papilloma development in mic e","volume":"16","author":"Lian","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","article-title":"Expanding control of the tumor cell cycle with a cdk2\/4\/6 inhibitor","volume":"39","author":"Freeman-Cook","year":"2021","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.04.037","article-title":"Cyclin e overexpression confers resistance to the cdk4\/6 specific inhi bitor palbociclib in gastric cancer cells","volume":"430","author":"Min","year":"2018","journal-title":"Cancer Lett"},{"key":"B41","doi-asserted-by":"publisher","first-page":"S0016","DOI":"10.1053\/j.gastro.2019.09.056","article-title":"Genomic and epigenomic features of primary and recurrent hepatocellula r carcinomas","volume":"157","author":"Ding","year":"2020","journal-title":"Gastroenterology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2019.1685289","article-title":"Co-targeting p53-r249s and cdk4 synergistically suppresses survival of hepatocellular carcinoma cells","volume":"21","author":"Wang","year":"2020","journal-title":"Cancer Biol Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adu2339","article-title":"Tp53missense-specific transcriptional plasticity drives resist ance against cell cycle inhibitors in pancreatic cancer","volume":"11","author":"Urbach","year":"2025","journal-title":"Sci Adv"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02719-2","article-title":"Dynll1 accelerates cell cycle via ilf2\/cdk4 axis to promote hepatocell ular carcinoma development and palbociclib sensitivity","volume":"131","author":"Liu","year":"2024","journal-title":"Br J Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12072","article-title":"Palbociclib induces activation of ampk and inhibits hepatocellular car cinoma in a cdk4\/6-independent manner","volume":"11","author":"Hsieh","year":"2017","journal-title":"Mol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000001095","article-title":"Reinventing nuclear histo-score utilizing inherent morphologic cutoffs : Blue-brown color h-score (bbc-hs)","volume":"31","author":"Price","year":"2023","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2023-0483-CP","article-title":"Principles of analytic validation of immunohistochemical assays: Guide line update","volume":"148","author":"Goldsmith","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing-based oncology panels: A joint consensus recommendation of the association for molec ular pathology and college of american pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagn"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"Esmo recommendations on the use of circulating tumour dna assays for p atients with cancer: A report from the esmo precision medicine working group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63511-0","article-title":"Aberrant cpg island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation","volume":"163","author":"Kang","year":"2003","journal-title":"Am J Pathol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","article-title":"Role of oncogenic Kras in the prognosis, diagnosis and treatment of co lorectal cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"Mol Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting Kras in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102418","article-title":"Resistance mechanisms to Her2-targeted therapy in gastroesophageal ade nocarcinoma: a systematic review","volume":"108","author":"Blang\u00e9","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052608","article-title":"Semaphorin 6c suppresses proliferation of pancreatic cancer cells via inhibition of the Akt\/Gsk3\/B-catenin\/cyclin D1 pathway","volume":"23","author":"Hung","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-019-00317-6","article-title":"Pak1 silencing is synthetic lethal with Cdk4\/6 inhibition in gastric c ancer cells via regulating Pdk1 expression","volume":"33","author":"Qian","year":"2020","journal-title":"Hum Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.7150\/thno.98389","article-title":"Batf2 inhibits the stem cell-like properties and chemoresistance of ga stric cancer cells through Pten\/Akt\/B-catenin pathway","volume":"14","author":"Cao","year":"2024","journal-title":"Theranostics"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-24-20","article-title":"Cdk4\/6 inhibition to resensitize Braf\/Egfr inhibitor in patient-derive d Braf\/Pten-mutant colon cancer cells","volume":"13","author":"Lim","year":"2024","journal-title":"Trans Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.07.015","article-title":"Mir-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models","volume":"29","author":"Callegari","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040801","article-title":"A regulatory noncoding Rna, Nc886, suppresses esophageal cancer by inh ibiting the Akt pathway and cell cycle progression","volume":"9","author":"Im","year":"2020","journal-title":"Cells"},{"key":"B60","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","article-title":"The Hippo pathway: Biology and pathophysiology","volume":"88","author":"Ma","year":"2019","journal-title":"Annu Rev Biochem"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0894-3","article-title":"Cyclin D1 is a mediator of gastrointestinal stromal tumor kit-independ ence","volume":"38","author":"Ou","year":"2019","journal-title":"Oncogene"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0589","article-title":"Abemaciclib is effective against pancreatic cancer cells and synergize s with Hur and Yap1 inhibition","volume":"17","author":"Dhir","year":"2019","journal-title":"Mol Cancer Res MCR"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.503","article-title":"Oncogenic Pax6 elicits Cdk4\/6 inhibitor resistance by epigenetically i nactivating the Lats2-Hippo signaling pathway","volume":"11","author":"Zhang","year":"2021","journal-title":"Clin Transl Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70103","article-title":"Targeting Cdk4\/6 suppresses colorectal cancer by destabilizing Yap1","volume":"6","author":"Wen","year":"2025","journal-title":"MedComm"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00026.2016","article-title":"Importance of the alternative Nf-Kb activation pathway in inflammation -associated gastrointestinal carcinogenesis","volume":"310","author":"Merga","year":"2016","journal-title":"Am J Physiol Gastrointestinal Liver Physiol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/toxins9040119","article-title":"Nf-Kb signaling in gastric cancer","volume":"9","author":"Sokolova","year":"2017","journal-title":"Toxins"},{"key":"B67","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.16439.1","article-title":"Recent advances in understanding inhibitor of apoptosis proteins","volume":"7","author":"Lalaoui","year":"2018","journal-title":"F1000Research"},{"key":"B68","doi-asserted-by":"publisher","first-page":"6826","DOI":"10.1038\/s41598-025-90997-y","article-title":"Cdk4\/6 inhibitors upregulate Ciap1\/2, and Smac mimetic Lcl161 enhances their antitumor effects in cholangiocarcinoma cells","volume":"15","author":"Menapree","year":"2025","journal-title":"Sci Rep"},{"key":"B69","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","article-title":"Notch signaling pathway in cancer: From mechanistic insights to target ed therapies","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B70","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13578-016-0077-7","article-title":"Misregulation of the proline rich homeodomain (Prh\/Hhex) protein in ca ncer cells and its consequences for tumour growth and invasion","volume":"6","author":"Gaston","year":"2016","journal-title":"Cell Bioscience"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0942","article-title":"A runaway Prh\/Hhex-Notch3-positive feedback loop drives cholangiocarci noma and determines response to Cdk4\/6 inhibition","volume":"80","author":"Kitchen","year":"2020","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12398","article-title":"Immunohistochemical and molecular analysis of Pi3k\/Akt\/Mtor pathway in esophageal carcinoma","volume":"123","author":"Tasioudi","year":"2015","journal-title":"APMIS"},{"key":"B73","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","article-title":"Yap\/Taz at the roots of cancer","volume":"29","author":"Zanconato","year":"2016","journal-title":"Cancer Cell"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12065","article-title":"Different cellular localization of Nf-Kb p65 expression as an indicato r of different prognoses of stage I-iii gastric cancer patients","volume":"6","author":"Zhou","year":"2013","journal-title":"Clin Transl Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2019.4418","article-title":"Precision medicine for human cancers with Notch signaling dysregulatio n (review)","volume":"45","author":"Katoh","year":"2020","journal-title":"Int J Mol Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.99","article-title":"Emerging roles of P53 and other tumour-suppressor genes in immune regu lation","volume":"16","author":"Mu\u00f1oz-Fontela","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016817","article-title":"Tumor microenvironment-mediated immune tolerance in development and tr eatment of gastric cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102629","article-title":"Regulatory T cells in gastric cancer: Key controllers from pathogenesi s to therapy","volume":"120","author":"Negura","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B79","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1053\/j.gastro.2021.11.037","article-title":"The origin and contribution of cancer-associated fibroblasts in colore ctal carcinogenesis","volume":"162","author":"Kobayashi","year":"2022","journal-title":"Gastroenterology"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/nature23465","article-title":"Cdk4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of Mhc class I antigen presentation","volume":"12","author":"DhatChinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwae034","article-title":"Endogenous retrovirus activation: Potential for immunology and clinica l applications","volume":"11","author":"Yu","year":"2024","journal-title":"Natl Sci Rev"},{"key":"B83","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12935-024-03322-4","article-title":"Targeted silencing of Socs1 by Dnmt1 promotes stemness of human liver cancer stem-like cells","volume":"24","author":"Lou","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-020-00526-4","article-title":"Dnmt1 as a therapeutic target in pancreatic cancer: Mechanisms and cli nical implications","volume":"43","author":"Wong","year":"2020","journal-title":"Cell Oncol (Dordrecht Netherlands)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13402-025-01136-8","article-title":"Decitabine promotes degradation of Dnmt1 and Ezh2 via the ubiquitinati on pathway and inhibits colorectal cancer progression","volume":"49","author":"Peng","year":"2025","journal-title":"Cell Oncol (Dordrecht Netherlands)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-017-0312-z","article-title":"The immunomodulatory anticancer agent, Rrx-001, induces an interferon response through epigenetic induction of viral mimicry","volume":"9","author":"Zhao","year":"2017","journal-title":"Clin Epigenet"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing vi ral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"B88","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13148-021-01014-8","article-title":"A feasibility study of combined epigenetic and vaccine therapy in adva nced colorectal cancer with pharmacodynamic endpoint","volume":"13","author":"Bever","year":"2021","journal-title":"Clin Epigenet"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.02.053","article-title":"The Cdk4\/6 inhibitor abemaciclib induces a T cell inflamed tumor micro environment and enhances the efficacy of Pd-L1 checkpoint blockade","volume":"22","author":"Schaer","year":"2018","journal-title":"Cell Rep"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202511330","article-title":"Cdk4\/6 inhibition induces Cd8+ T cell antitumor immunity vi a Mif-induced functional orchestration of tumor-associated macrophages","author":"He","year":"2025","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"Cdk4\/6 inhibition augments antitumor immunity by enhancing T-cell acti vation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"},{"key":"B92","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12935-024-03351-z","article-title":"Cdk4\/6 inhibition enhances T-cell immunotherapy on hepatocellular carc inoma cells by rejuvenating immunogenicity","volume":"24","author":"Cai","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/nature25015","article-title":"Cyclin D-Cdk4 kinase destabilizes Pd-L1 via Cullin 3-Spop to control c ancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molcel.2018.10.034","article-title":"Phosphorylated Rb promotes cancer immunity by inhibiting Nf-Kb activat ion and Pd-L1 expression","volume":"73","author":"Jin","year":"2019","journal-title":"Mol Cell"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.11.010","article-title":"Cellular senescence offers distinct immunological vulnerabilities in c ancer","volume":"11","author":"Zhou","year":"2025","journal-title":"Trends Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cell.2020.03.008","article-title":"Senescence-induced vascular remodeling creates therapeutic vulnerabili ties in pancreas cancer","volume":"181","author":"Ruscetti","year":"2020","journal-title":"Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170532","article-title":"Cell cycle inhibitors activate the hypoxia-induced Ddx41\/Sting pathway to mediate antitumor immune response in liver cancer","volume":"9","author":"Wong","year":"2024","journal-title":"JCI Insight"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15961","article-title":"Combination of Parp inhibitor and Cdk4\/6 inhibitor modulates Cgas\/Stin g-dependent therapy-induced senescence and provides \"one-two punch\" opportunity with anti-Pd-L1 therapy in colorectal cancer","volume":"114","author":"Wang","year":"2023","journal-title":"Cancer Sci"},{"key":"B99","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-023-01359-x","article-title":"Intact regulation of G1\/S transition renders esophageal squamous cell carcinoma sensitive to Pi3k\u03b1 inhibitors","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323276","article-title":"Pan-erbb kinase inhibition augments cdk4\/6 inhibitor efficacy in oesop hageal squamous cell carcinoma","volume":"71","author":"Zhou","year":"2022","journal-title":"Gut"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1029","article-title":"Yap1-mediated cdk6 activation confers radiation resistance in esophage al cancer - rationale for the combination of yap1 and cdk4\/6 inhibitor s in esophageal cancer","volume":"25","author":"Li","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/s41467-019-09179-w","article-title":"Targeting glutamine-addiction and overcoming cdk4\/6 inhibitor resistan ce in human esophageal squamous cell carcinoma","volume":"10","author":"Qie","year":"2019","journal-title":"Nat Commun"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-023-2789-3","article-title":"Inhibition of eukaryotic initiating factor eif4e overcomes abemaciclib resistance in gastric cancer","volume":"43","author":"Zha","year":"2023","journal-title":"Curr Med Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.148","article-title":"Pyrotinib combined with cdk4\/6 inhibitor in her2-positive metastatic g astric cancer: a promising strategy from avatar mouse to patients","volume":"10","author":"Chen","year":"2020","journal-title":"Clin Transl Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1158\/1078-0432.CCR-22-1609","article-title":"Development of combination strategies for focal adhesion kinase inhibi tion in diffuse gastric cancer","volume":"29","author":"Peng","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13046-023-02615-2","article-title":"The brd4 inhibitor jq1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma","volume":"42","author":"Feng","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41419-021-04206-5","article-title":"Alpelisib combination treatment as novel targeted therapy against hepa tocellular carcinoma","volume":"12","author":"Xu","year":"2021","journal-title":"Cell Death Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14728","article-title":"Ribociclib enhances infigratinib-induced cancer cell differentiation a nd delays resistance in fgfr-driven hepatocellular carcinoma","volume":"41","author":"Prawira","year":"2021","journal-title":"Liver Int"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31872","article-title":"Treatment of retinoblastoma 1-intact hepatocellular carcinoma with cyc lin-dependent kinase 4\/6 inhibitor combination therapy","volume":"74","author":"Sheng","year":"2021","journal-title":"Hepatol (Baltimore Md)"},{"key":"B110","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12885-020-06822-4","article-title":"Modulation of sirt3 expression through cdk4\/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells","volume":"20","author":"Jo","year":"2020","journal-title":"BMC Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.563249","article-title":"Simultaneous combination of the cdk4\/6 inhibitor palbociclib with rego rafenib induces enhanced anti-tumor effects in hepatocarcinoma cell li nes","volume":"10","author":"Digiacomo","year":"2020","journal-title":"Front Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2024.01.025","article-title":"Dual inhibition of cdk4\/6 and xpo1 induces senescence with acquired vu lnerability to crbn-based protac drugs","volume":"166","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0284","article-title":"Combined cdk4\/6 and pan-mtor inhibition is synergistic against intrahe patic cholangiocarcinoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.018","article-title":"Focal adhesion kinase (fak) promotes cholangiocarcinoma development an d progression via yap activation","volume":"75","author":"Song","year":"2021","journal-title":"J Hepatol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/hep.32102","article-title":"Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4\/6 inhibitors in biliary tract cancers","volume":"75","author":"Arora","year":"2022","journal-title":"Hepatol (Baltimore Md)"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-0391","article-title":"Combination therapies with cdk4\/6 inhibitors to treat kras-mutant panc reatic cancer","volume":"83","author":"Goodwin","year":"2023","journal-title":"Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2923","article-title":"Cdk4\/6 and igf1 receptor inhibitors synergize to suppress the growth o f p16ink4a-deficient pancreatic cancers","volume":"74","author":"Heilmann","year":"2014","journal-title":"Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0082","article-title":"Cyclooxygenase-2 influences response to cotargeting of mek and cdk4\/6 in a subpopulation of pancreatic cancers","volume":"17","author":"Maust","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3761","article-title":"Concomitant mek and cyclin gene alterations: implications for response to targeted therapeutics","volume":"27","author":"Kato","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1043","article-title":"Combined blockade of mek and cdk4\/6 pathways induces senescence to imp rove survival in pancreatic ductal adenocarcinoma","volume":"20","author":"Willobee","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B121","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/pancan.2020.0005","article-title":"A phase i study of ribociclib plus everolimus in patients with metasta tic pancreatic adenocarcinoma refractory to chemotherapy","volume":"6","author":"Weinberg","year":"2020","journal-title":"J Pancreat Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1186\/s12885-023-11464-3","article-title":"A real-world analysis of trametinib in combination with hydroxychloroq uine or cdk4\/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma","volume":"23","author":"Tang","year":"2023","journal-title":"BMC Cancer"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0562","article-title":"Cdk4\/6 inhibition induces epithelial-mesenchymal transition and enhanc es invasiveness in pancreatic cancer cells","volume":"11","author":"Liu","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.7150\/jca.26068","article-title":"Antitumor activity of sorafenib plus cdk4\/6 inhibitor in pancreatic pa tient derived cell with kras mutation","volume":"9","author":"Lee","year":"2018","journal-title":"J Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0072","article-title":"A preclinical and phase ib study of palbociclib plus nab-paclitaxel in patients with metastatic adenocarcinoma of the pancreas","volume":"2","author":"Hidalgo","year":"2022","journal-title":"Cancer Res Commun"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-1102-1","article-title":"Chemotherapy impacts on the cellular response to cdk4\/6 inhibition: di stinct mechanisms of interaction and efficacy in models of pancreatic cancer","volume":"39","author":"Kumarasamy","year":"2020","journal-title":"Oncogene"},{"key":"B127","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2020.01.007","article-title":"Cdk4\/6 inhibitors impair recovery from cytotoxic chemotherapy in pancr eatic adenocarcinoma","volume":"37","author":"Salvador-Barbero","year":"2020","journal-title":"Cancer Cell"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413264","article-title":"Synergistic effects of the combination of Alpelisib (Pi3k inhibitor) a nd Ribociclib (Cdk4\/6 inhibitor) in preclinical colorectal cancer mode ls","volume":"25","author":"Aslam","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2023.2223388","article-title":"Preclinical evaluation of the cdk4\/6 inhibitor palbociclib in combinat ion with a pi3k or mek inhibitor in colorectal cancer","volume":"24","author":"Lee","year":"2023","journal-title":"Cancer Biol Ther"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.120","article-title":"Oncogenic kras-associated gene signature defines co-targeting of cdk4\/ 6 and mek as a viable therapeutic strategy in colorectal cancer","volume":"36","author":"Pek","year":"2017","journal-title":"Oncogene"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-0198","article-title":"Targeting ras mutant colorectal cancer with dual inhibition of mek and cdk4\/6","volume":"82","author":"Sorokin","year":"2022","journal-title":"Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.384","article-title":"Raf inhibitor ly3009120 sensitizes ras or braf mutant cancer to cdk4\/6 inhibition by abemaciclib via superior inhibition of phospho-rb and s uppression of cyclin d1","volume":"37","author":"Chen","year":"2018","journal-title":"Oncogene"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf305","article-title":"Phase ii single-arm study of palbociclib and cetuximab in anti-egfr na \u00efve patients with kras\/nras\/braf wild-type, metastatic colorectal canc er","volume":"30","author":"Sorah","year":"2025","journal-title":"Oncologist"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-025-01502-x","article-title":"Enhancement of colorectal cancer therapy through interruption of the h sf1-hsp90 axis by p53 activation or cell cycle inhibition","volume":"32","author":"Isermann","year":"2025","journal-title":"Cell Death Differ"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202413618","article-title":"Allosteric cdc37 inhibitor disrupts chaperone complex to block cdk4\/6 maturation","volume":"64","author":"Zhang","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"key":"B136","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41598-018-36447-4","article-title":"A novel tankyrase inhibitor, msc2504877, enhances the effects of clini cal cdk4\/6 inhibitors","volume":"9","author":"Menon","year":"2019","journal-title":"Sci Rep"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2022.07.005","article-title":"Additive effect of cd73 inhibitor in colorectal cancer treatment with cdk4\/6 inhibitor through regulation of pd-l1","volume":"14","author":"Noh","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2017.1320005","article-title":"The cdk4\/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia","volume":"16","author":"Zhang","year":"2017","journal-title":"Cell Cycle (Georgetown Tex)"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1309509","article-title":"The combination of il-2 nanoparticles and palbociclib enhances the ant i-tumor immune response for colon cancer therapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.4c06018","article-title":"Iterative design of a prodrug nanocarrier for cell cycle arrest, immun e modulation, and enhanced t cell infiltration for colon cancer therap y","volume":"25","author":"Feng","year":"2025","journal-title":"Nano Lett"},{"key":"B141","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bcp.2016.10.015","article-title":"Effect of abemaciclib (ly2835219) on enhancement of chemotherapeutic a gents in abcb1 and abcg2 overexpressing cells in vitro and in vivo","volume":"124","author":"Wu","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12932","article-title":"Phase i study of palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, in Japanese patients","volume":"107","author":"Tamura","year":"2016","journal-title":"Cancer Sci"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13428","article-title":"Phase i study of single-agent ribociclib in Japanese patients with adv anced solid tumors","volume":"109","author":"Doi","year":"2018","journal-title":"Cancer Sci"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-024-00727-x","article-title":"The senescence-associated secretory phenotype and its physiological an d pathological implications","volume":"25","author":"Wang","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0060301","article-title":"Senescence-associated secretory phenotypes reveal cell-nonautonomous f unctions of oncogenic ras and the p53 tumor suppressor","volume":"6","author":"Copp\u00e9","year":"2008","journal-title":"PLoS Biol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12943-025-02475-8","article-title":"The controversial role of senescence-associated secretory phenotype (sasp) in cancer therapy","volume":"24","author":"Cao","year":"2025","journal-title":"Mol Cancer"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00586-18","article-title":"Uncoupling the senescence-associated secretory phenotype from cell cyc le exit via interleukin-1 inactivation unveils its protumorigenic role","volume":"39","author":"Lau","year":"2019","journal-title":"Mol Cell Biol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00553-8","article-title":"Ezh2 inhibition remodels the inflammatory senescence-associated secret ory phenotype to potentiate pancreatic cancer immune surveillance","volume":"4","author":"Chibaya","year":"2023","journal-title":"Nat Cancer"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3390\/cells14191498","article-title":"Mm-129 counteracts 5-fluorouracil-induced cellular senescence in colon cancer via sirt1\/stat3 signaling pathway","volume":"14","author":"Klepacki","year":"2025","journal-title":"Cells"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1845921\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:35:52Z","timestamp":1780551352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1845921\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":149,"alternative-id":["10.3389\/fimmu.2026.1845921"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1845921","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"article-number":"1845921"}}